查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423390

2024-2032 年按產品類型（藥物、輸送裝置）、配銷通路（零售藥房、醫院藥房、線上零售店等）、疾病類型（I 型糖尿病、II 型糖尿病）和地區分類的人胰島素市場報告

Human Insulin Market Report by Product Type (Drugs, Delivery Devices), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Retail Stores, and Others), Disease Type (Type I Diabetes, Type II Diabetes), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2023年全球人類胰島素市場規模達到482億美元。展望未來， IMARC Group預計到2032年市場規模將達到842億美元，2024-2032年複合年成長率（CAGR）為6.2%。糖尿病發病率不斷上升、老年人口不斷增加、人類胰島素生產的快速發展、廣泛的研發（R＆D）活動以及政府支持政策的實施是推動市場的一些主要因素。

人類胰島素是一種胜肽類激素，是人體內葡萄糖代謝的重要調節劑。它是由胰臟BETA細胞產生，在維持正常血糖水平方面發揮重要作用。人類胰島素有多種形式，包括短效、中效和長效製劑。它廣泛用於治療第一型糖尿病、糖尿病酮酸中毒（DKA）、妊娠糖尿病和第2型糖尿病。它有助於實現最佳血糖控制並最大限度地降低與疾病相關的長期併發症的風險。人類胰島素也具有更高的安全性和功效，因為它非常模仿人體的天然胰島素產生。

政府實施支持性政策來提高人們對糖尿病治療的認知並提供高品質的醫療設施，這有助於市場的成長。此外，個人化醫療和精準治療的趨勢轉變正在促進產品需求，因為它允許劑量調整和客製化胰島素治療方案，從而改善患者的治療效果。除此之外，製造商為提高品牌知名度、提高知名度和吸引新客戶而進行的積極行銷和促銷活動正在推動市場成長。此外，大眾對人類胰島素重要性的認知和教育不斷增強，正在支持市場的成長。其他因素，包括醫療保健基礎設施的快速擴張、對開發先進生產方法的投資增加以及主要參與者之間不斷增強的合作夥伴關係，預計將推動市場成長。

人類胰島素市場趨勢/促進因素：

糖尿病發生率不斷上升

人類胰島素在糖尿病的治療和管理中發揮著至關重要的作用，糖尿病是一種以血糖水平升高為特徵的慢性代謝性疾病。它廣泛應用於胰島素替代、個人化治療和特定病症的管理。此外，在第 1 型糖尿病治療中廣泛使用產品來提供人體無法產生的必需胰島素，從而幫助調節血糖水平和預防高血糖，正在支持市場成長。此外，它也被用作口服藥物，以補充人體的胰島素供應並提高葡萄糖的利用率。除此之外，胰島素幫浦療法中越來越多的產品被採用，以模仿健康胰臟的基礎胰島素分泌，全天持續供應胰島素，這也促進了市場的成長。此外，人類胰島素在術前和重症監護環境中發揮關鍵作用，以防止血糖波動並降低手術併發症的風險。

老年人口不斷增加

人類胰島素在患有糖尿病的老年人群中實現最佳血糖控制方面發揮著至關重要的作用。它可以根據年齡、病史、腎功能和整體健康狀況等因素進行個別化治療和精確的劑量調整，以滿足老年人的特定需求。此外，人類胰島素具有完善的安全性，並且在糖尿病治療中使用了數十年，與新療法相比，它對老年人群的風險較小。此外，與某些其他糖尿病藥物相比，它有助於最大限度地降低老年族群低血糖的風險。除此之外，人類胰島素可以透過多種方式給藥，包括胰島素筆、注射器和胰島素泵，這使得醫療保健提供者可以根據老年人的需求和偏好選擇最合適的胰島素輸送方法。

人類胰島素生產的快速進步

重組脫氧核糖核酸（DNA）技術的引入消除了對動物胰島素萃取的需要，並提供了更一致和可靠的胰島素來源，對市場成長產生了積極影響。此外，利用連續製造流程可以連續不間斷地生產胰島素，從而提高效率和生產率，減少時間，節省成本，並能夠快速回應需求變化，從而促進了市場的成長。此外，生物加工技術的最新進展，例如發酵條件、培養基配方和細胞培養過程的最佳化，有助於降低生產成本，同時保持高產品質量，支持市場成長。此外，整合先進的加工技術（例如色譜、過濾和親和分離）以提高胰島素純化的效率和效果，正在加強市場成長。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球人類胰島素市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品類型

  • 藥品
    • 市場走向
    • 市場區隔：按類型
      • 人類胰島素類似物和生物相似藥
        • 快速行動
        • 市場走向
        • 市場預測
        • 長效
        • 市場走向
        • 市場預測
        • 預混
        • 市場走向
        • 市場預測
      • 人類胰島素生物製劑
        • 短動作
        • 市場走向
        • 市場預測
        • 中級表演
        • 市場走向
        • 市場預測
        • 預混
        • 市場走向
        • 市場預測
    • 市場預測
  • 輸送裝置
    • 市場走向
    • 市場區隔：按類型
      • 鋼筆
        • 可重複使用的筆
        • 免洗筆
      • 筆針
        • 標準筆針
        • 安全筆針
      • 注射器
      • 其他
    • 市場預測

第 7 章：市場區隔：按配銷通路

  • 零售藥局
    • 市場走向
    • 市場預測
  • 醫院藥房
    • 市場走向
    • 市場預測
  • 網路零售店
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依疾病類型

  • I 型糖尿病
    • 市場走向
    • 市場預測
  • II型糖尿病
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太地區
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格指標

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company (BD)
    • Biocon
    • Eli Lilly and Company
    • Gulf Pharmaceutical Industries (Julphar)
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Groupe Sanofi
    • SEDICO Co.
    • Wockhardt Limited
    • Ypsomed AG
Product Code: SR112024A1950

Abstract

The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The growing incidences of diabetes, rising geriatric population, rapid advancements in human insulin production, extensive research and development (R&D) activities, and the implementation of supportive government policies are some of the major factors propelling the market.

Human insulin refers to a peptide hormone that serves as a vital regulator of glucose metabolism within the human body. It is produced by pancreatic beta cells and plays a fundamental role in maintaining normal blood sugar levels. Human insulin is available in various forms, including short-acting, intermediate-acting, and long-acting formulations. It is widely used for the management of type 1 diabetes, diabetic ketoacidosis (DKA), gestational diabetes, and type 2 diabetes. It aids in achieving optimal blood glucose control and minimizing the risk of long-term complications associated with the disease. Human insulin also offers enhanced safety and efficacy profile, as it closely mimics the body's natural insulin production.

The implementation of supportive government policies to increase awareness regarding diabetes treatment and provide access to high-quality healthcare facilities is contributing to the market growth. Furthermore, the shifting trends towards personalized medicine and precision therapies are facilitating product demand as it allows dosage adjustments and customized insulin regimens, which improves patient outcomes. Besides this, aggressive marketing and promotional activities by manufacturers to improve brand visibility, increase awareness, and attract new customers are propelling the market growth. Moreover, the growing awareness and education among the masses regarding the importance of human insulin is supporting the market growth. Other factors, including the rapid expansion of the healthcare infrastructure, increasing investment in developing advanced production methods, and growing partnerships between key players, are anticipated to drive the market growth.

Human Insulin Market Trends/Drivers:

The growing incidences of diabetes

Human insulin plays a vital role in the treatment and management of diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels. It is widely used in insulin replacement, individualized therapy, and the management of specific conditions. Furthermore, the widespread product utilization in type 1 diabetes treatment to provide necessary insulin that bodies cannot produce, thus aiding in regulating blood sugar levels and preventing hyperglycemia, is supporting the market growth. Additionally, it is taken as an oral medication to supplement the body's insulin supply and improve glucose utilization. Apart from this, the rising product adoption in insulin pump therapy to deliver a continuous supply of insulin throughout the day, mimicking the basal insulin secretion of a healthy pancreas, is contributing to the market growth. Moreover, human insulin plays a critical role in preoperative and critical care settings to prevent glucose fluctuations and reduce the risks of surgical complications.

The rising geriatric population

Human insulin plays a crucial role in achieving optimal glycemic control in the geriatric population suffering from diabetes. It allows for individualized therapy and precise dosage adjustments to meet the specific needs of aging individuals based on factors such as age, medical history, renal function, and overall health status. Furthermore, human insulin has a well-established safety profile and has been used for decades in the treatment of diabetes, making it less risky for the geriatric population compared to newer treatments. Additionally, it aids in minimizing the risk of hypoglycemia in the elderly population compared to certain other diabetes medications. Apart from this, human insulin can be administered through various methods, including insulin pens, syringes, and insulin pumps, which allows healthcare providers to choose the most appropriate insulin delivery method based on the needs and preferences of geriatric individuals.

Rapid advancements in human insulin production

The introduction of recombinant deoxyribonucleic acid (DNA) technology, which eliminates the need for animal-based insulin extraction and provides a more consistent and reliable source of insulin, is positively influencing the market growth. Furthermore, the utilization of a continuous manufacturing process, which improves efficiency and productivity by allowing continuous and uninterrupted production of insulin, reducing time, saving cost, and enabling rapid response to changes in demand, is contributing to the market growth. Additionally, the recent advancements in bioprocessing techniques, such as the optimization of fermentation conditions, media formulation, and cell culture processes, which aid in reducing production costs while maintaining high product quality, are supporting the market growth. Moreover, the integration of advanced processing techniques, such as chromatography, filtration, and affinity-based separations, to improve the efficiency and effectiveness of insulin purification is strengthening the market growth.

Human Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human insulin market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, distribution channel, and disease type.

Breakup by Product Type:

Drugs

Human Insulin Analogs and Biosimilars

Rapid Acting

Long Acting

Premixed

Human Insulin Biologics

Short Acting

Intermediate Acting

Premixed

Delivery Devices

Pens

Reusable Pens

Disposable Pens

Pen Needles

Standard Pen Needles

Safety Pen Needles

Syringes

Others

Drugs dominate the market

The report has provided a detailed breakup and analysis of the market based on the product type. This includes drugs (human insulin analogs and biosimilars (rapid acting, long acting, and premixed) and human insulin biologics (short acting, intermediate acting, and premixed)) and delivery devices (pens (reusable pens and disposable pens), pen needles (standard pen needles and safety pen needles), syringes, and others). According to the report, drugs represented the largest market segment.

Drugs are dominating the market growth as they have been extensively researched and proven to be effective in managing diabetes. Furthermore, their established market presence has created familiarity and confidence among prescribers, leading to their continued dominance. Apart from this, human insulin drugs are generally more accessible and affordable compared to newer, patented insulin alternatives. Their easy accessibility and affordability have contributed to the widespread use of these drugs, particularly in resource-limited settings. Besides this, they have received regulatory approvals from health authorities around the world, which ensure that human insulin drugs meet quality standards and efficacy requirements. Moreover, human insulin drugs have been widely accepted by patients with diabetes due to their long history of use and proven effectiveness.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Retail Stores

Others

Retail Pharmacies dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, online retail stores, and others. According to the report, the distribution channel represented the largest market segment.

Retail pharmacies are situated in easily accessible locations, such as shopping centers, neighborhoods, and urban areas, which makes it convenient for patients with diabetes to access their prescribed medications. Furthermore, they have an extensive network of stores with multiple locations across cities, regions, and countries, which ensures that patients can find a nearby retail pharmacy to fill their human insulin prescriptions, irrespective of their location. Additionally, retail pharmacies have established relationships with various insurance providers and government healthcare programs, allowing for smooth reimbursement processes. Moreover, they provide additional services beyond prescription dispensing, including the proper use of human insulin, injection techniques, blood glucose monitoring, and lifestyle modifications.

Breakup by Disease Type:

Type I Diabetes

Type II Diabetes

Type I diabetes holds the largest market share

The report has provided a detailed breakup and analysis of the market based on the disease type. This includes type I and type II diabetes. According to the report, type I diabetes represented the largest market segment.

Type 1 diabetes holds the majority market share owing to its widespread prevalence across the globe. Furthermore, individuals with type 1 diabetes require insulin from the time of diagnosis throughout their lives. This substantial need for human insulin necessitates its steady supply to meet the rising demand for insulin replacement therapy. Furthermore, the absence of natural insulin production in type 1 diabetes creates a significant market demand as the primary source of insulin replacement. Along with this, human insulin provides a closer match to the insulin needs of individuals with type 1 diabetes compared to other insulin analogs, as it is structurally identical to the insulin naturally produced in the human body.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market, accounting for the largest human insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market segment.

North America is dominating the market as it has a significant burden of diabetes, with both type 1 and type 2 diabetes being prevalent in the region. Furthermore, it boasts a well-developed healthcare infrastructure characterized by advanced medical facilities, research institutions, and pharmaceutical companies, which supports the production, distribution, and accessibility of human insulin. Additionally, North America is at the forefront of technological advancements in the healthcare sector, including the development of innovative insulin delivery systems, such as insulin pens and insulin pumps, which enhance the administration and effectiveness of human insulin. Moreover, the presence of several leading pharmaceutical companies that are actively engaged in the production and distribution of human insulin is acting as another growth-inducing factor. Apart from this, North America has well-established regulatory bodies which ensure the safety, efficacy, and quality of pharmaceutical products, including human insulin.

Competitive Landscape:

The leading companies in the market are investing in research and development (R&D) projects to create innovative human insulin products. They are focusing on improving the pharmacokinetics, delivery systems, and formulations of insulin to enhance patient convenience and adherence. Apart from this, companies are expanding their presence in emerging markets due to the growing diabetic population and increasing healthcare access. Additionally, they are establishing partnerships with local distributors, healthcare providers, and regulatory authorities to navigate the regulatory landscape and ensure the availability of their human insulin products. Moreover, several key players are developing a range of insulin formulations with varying durations of action, which allows them to capture a broader market share and meet the specific requirements of patients with different types of diabetes.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

B. Braun Melsungen AG

Becton

Dickinson and Company (BD)

Biocon

Eli Lilly and Company

Gulf Pharmaceutical Industries (Julphar)

Novo Nordisk A/S

Pfizer Inc.

Groupe Sanofi

SEDICO Co.

Wockhardt Limited

Ypsomed AG

Recent Developments:

In December 2021, Dickinson and Company (BD) announced that "embecta" will be the name of the publicly-traded company that will hold BD's Diabetes Care business.

In November 2022, Biocon Sdn. Bhd., a subsidiary of Biocon in Malaysia, announced that it had been awarded a three-year contract for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.

In February 2023, Eli Lilly and Company announced a partnership with International Agencies (Bangladesh) Ltd. (IABL) to ensure access to high-quality, affordable insulin in Bangladesh.

Key Questions Answered in This Report

  • 1. What was the size of the global human insulin market in 2023?
  • 2. What is the expected growth rate of the global human insulin market during 2024-2032?
  • 3. What are the key factors driving the global human insulin market?
  • 4. What has been the impact of COVID-19 on the global human insulin market?
  • 5. What is the breakup of the global human insulin market based on the product type?
  • 6. What is the breakup of the global human insulin market based on the distribution channel?
  • 7. What is the breakup of the global human insulin market based on the disease type?
  • 8. What are the key regions in the global human insulin market?
  • 9. Who are the key players/companies in the global human insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Breakup by Type
      • 6.1.2.1 Human Insulin Analogs and Biosimilars
        • 6.1.2.1.1 Rapid Acting
        • 6.1.2.1.1.1 Market Trends
        • 6.1.2.1.1.2 Market Forecast
        • 6.1.2.1.2 Long Acting
        • 6.1.2.1.2.1 Market Trends
        • 6.1.2.1.2.2 Market Forecast
        • 6.1.2.1.3 Premixed
        • 6.1.2.1.3.1 Market Trends
        • 6.1.2.1.3.2 Market Forecast
      • 6.1.2.2 Human Insulin Biologics
        • 6.1.2.2.1 Short Acting
        • 6.1.2.2.1.1 Market Trends
        • 6.1.2.2.1.2 Market Forecast
        • 6.1.2.2.2 Intermediate Acting
        • 6.1.2.2.2.1 Market Trends
        • 6.1.2.2.2.2 Market Forecast
        • 6.1.2.2.3 Premixed
        • 6.1.2.2.3.1 Market Trends
        • 6.1.2.2.3.2 Market Forecast
    • 6.1.3 Market Forecast
  • 6.2 Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Breakup by Type
      • 6.2.2.1 Pens
        • 6.2.2.1.1 Reusable Pens
        • 6.2.2.1.2 Disposable Pens
      • 6.2.2.2 Pen Needles
        • 6.2.2.2.1 Standard Pen Needles
        • 6.2.2.2.2 Safety Pen Needles
      • 6.2.2.3 Syringes
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hospital Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Retail Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Type I Diabetes
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type II Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 B. Braun Melsungen AG
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Becton, Dickinson and Company (BD)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biocon
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Gulf Pharmaceutical Industries (Julphar)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novo Nordisk A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Groupe Sanofi
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SEDICO Co.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Wockhardt Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Ypsomed AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Human Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Insulin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Human Insulin Market: Breakup by Product Type (in %), 2023
  • Figure 4: Global: Human Insulin Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Human Insulin Delivery Devices Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Human Insulin Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Human Insulin Market: Breakup by Disease Type (in %), 2023
  • Figure 8: Global: Human Insulin Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Human Insulin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 10: Global: Human Insulin (Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Human Insulin Drugs (Analogs and Biosimilars) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Human Insulin Drugs (Analogs and Biosimilars) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Human Insulin Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Human Insulin Drugs (Biologics - Short Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Human Insulin Drugs (Biologics - Short Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Human Insulin Drugs (Biologics - Premixed) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Human Insulin Drugs (Biologics - Premixed) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Human Insulin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Human Insulin (Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Human Insulin (Delivery Devices) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Human Insulin Delivery Devices (Pens) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Human Insulin Delivery Devices (Pens) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Human Insulin Delivery Devices (Pen Needles) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Human Insulin Delivery Devices (Pen Needles) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Human Insulin Delivery Devices (Syringes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Human Insulin Delivery Devices (Syringes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Human Insulin Delivery Devices (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Human Insulin Delivery Devices (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Human Insulin (Delivery Devices) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Human Insulin Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 39: Global: Human Insulin Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 40: Global: Human Insulin Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 41: Global: Human Insulin Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 42: Global: Human Insulin Market: Sales through Online Retail Stores (in Million US$), 2018 & 2023
  • Figure 43: Global: Human Insulin Market Forecast: Sales through Online Retail Stores (in Million US$), 2024-2032
  • Figure 44: Global: Human Insulin Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 45: Global: Human Insulin Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 46: Global: Human Insulin (Type I Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Global: Human Insulin (Type I Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Global: Human Insulin (Type II Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Global: Human Insulin (Type II Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: North America: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: North America: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United States: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United States: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Canada: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Canada: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Asia Pacific: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Asia Pacific: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: China: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: China: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Japan: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Japan: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: India: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: India: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: South Korea: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: South Korea: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Australia: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Australia: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Indonesia: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Indonesia: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Europe: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Europe: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Germany: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Germany: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: France: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: France: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: United Kingdom: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: United Kingdom: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Italy: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Italy: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Spain: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Spain: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Russia: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Russia: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Latin America: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Latin America: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Brazil: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Brazil: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Mexico: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 93: Mexico: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 94: Others: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 95: Others: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 96: Middle East and Africa: Human Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 97: Middle East and Africa: Human Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 98: Global: Human Insulin Industry: SWOT Analysis
  • Figure 99: Global: Human Insulin Industry: Value Chain Analysis
  • Figure 100: Global: Human Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Insulin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Human Insulin Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Human Insulin Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Human Insulin Delivery Devices Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 5: Global: Human Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Human Insulin Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 7: Global: Human Insulin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: Human Insulin Market: Competitive Structure
  • Table 9: Global: Human Insulin Market: Key Players